BridgeBio Oncology Therapeutics (BBOT) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Net selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 9, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Pedro Beltran, CEO, President sold 1,870 shares at $1.84 ($3K).
- Trade date
- Nov 18, 2026
- Disclosed to the SEC
- Nov 20, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All BBOT insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
BBOT insider transactions (Form 4)
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 20 NewSEC | Pedro BeltranCEO, President | Sell Plan | 1,87041,659 held (−4%) | $1.84 | $3K | -1.2% | — |
| Nov 17SEC | Marc CoboPrincipal Accounting Officer | Sell Plan | 7813,734 held (−1%) | $2.37 | $185 | -23.2% | — |
Similar past setups: not applicable. BBOT has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with BBOT in the Research Lab
BBOT has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
BridgeBio Oncology Therapeutics insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 2 sold $4K of BBOT stock on the open market.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings · How we calculate this
BBOT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $4K | 2 |
Valuation, profit and volume
Valuation figures for BBOT are refreshed each weekday; some aren't published for every company. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 BridgeBio Oncology Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 2 insiders reported sales totaling $4K. 2 of 2 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
BBOT earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 10, 2026 | -13.5% | None | +11.3%S&P +0.9% | pending |
| Aug 11, 2026 | +5.2% | None | +1.5%S&P -0.1% | -47.5% |
| May 12, 2026 | -10.1% | None | +2.4%S&P +0.4% | -4.1% |
| Mar 5, 2026 | -4.6% | None | +2.5%S&P -1.9% | -14.5% |
| Nov 12, 2025 | +12.7% | None | -2.9%S&P -1.6% | +1.7% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insiders at BridgeBio Oncology Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Pedro BeltranCEO, President | — | $3K | Nov 20, 2026 | — | — |
| Marc CoboPrincipal Accounting Officer | — | $185 | Nov 17, 2026 | — | — |
BBOT stock: common questions
Are BridgeBio Oncology Therapeutics, Inc. insiders buying BBOT stock?
No. No BridgeBio Oncology Therapeutics, Inc. insider reported an open-market purchase of BBOT in the past 12 months.
Are BridgeBio Oncology Therapeutics, Inc. insiders selling BBOT stock?
2 insiders reported sales worth $4K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is BBOT's 52-week range?
Over the past year BBOT has traded between $1.80 and $13.69. It last closed at $1.82 on Nov 20, 2026.